CII
VRTX icon

Capital International Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital International Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.7M Buy
164,407
+2,684
+2% +$1.19M 0.57% 45
2026
Q1 		$72.2M Buy
161,723
+2,063
+1% +$962K 0.56% 49
2025
Q4 		$72.4M Sell
159,660
-31,681
-17% -$13.7M 0.57% 40
2025
Q3 		$74.9M Buy
191,341
+16,108
+9% +$6.73M 0.6% 41
2025
Q2 		$78M Buy
175,233
+44,008
+34% +$20.3M 0.76% 35
2025
Q1 		$63.6M Buy
131,225
+7,091
+6% +$3.3M 0.77% 30
2024
Q4 		$50M Buy
124,134
+13,781
+12% +$6.39M 0.59% 47
2024
Q3 		$51.3M Buy
110,353
+4,171
+4% +$2M 0.65% 45
2024
Q2 		$49.8M Buy
106,182
+7,657
+8% +$3.32M 0.66% 41
2024
Q1 		$41.2M Buy
98,525
+20,482
+26% +$8.66M 0.56% 56
2023
Q4 		$31.8M Buy
78,043
+16,102
+26% +$5.95M 0.5% 57
2023
Q3 		$21.5M Buy
61,941
+5,552
+10% +$1.94M 0.41% 74
2023
Q2 		$19.8M Buy
56,389
+17,771
+46% +$5.99M 0.36% 79
2023
Q1 		$12.2M Buy
38,618
+1,187
+3% +$356K 0.24% 109
2022
Q4 		$10.8M Sell
37,431
-5,379
-13% -$1.64M 0.23% 119
2022
Q3 		$12.4M Sell
42,810
-16,624
-28% -$4.78M 0.28% 105
2022
Q2 		$16.7M Sell
59,434
-622
-1% -$166K 0.23% 124
2022
Q1 		$15.7M Sell
60,056
-47,117
-44% -$11.2M 0.18% 134
2021
Q4 		$23.5M Buy
107,173
+13,572
+14% +$2.64M 0.22% 123
2021
Q3 		$17M Sell
93,601
-21,698
-19% -$4.24M 0.16% 135
2021
Q2 		$23.2M Sell
115,299
-644
-0.6% -$135K 0.21% 125
2021
Q1 		$24.9M Sell
115,943
-101,543
-47% -$22.3M 0.23% 119
2020
Q4 		$51.4M Buy
217,486
+1,545
+0.7% +$354K 0.48% 78
2020
Q3 		$58.8M Buy
215,941
+11,780
+6% +$3.25M 0.65% 53
2020
Q2 		$59.3M Buy
204,161
+42,547
+26% +$11.5M 0.72% 44
2020
Q1 		$38.5M Buy
161,614
+22,414
+16% +$5.14M 0.65% 64
2019
Q4 		$30.5M Buy
+139,200
New +$28.2M 0.42% 92
2019
Q3 		– Sell
-19,615
Closed -$3.6M – 246
2019
Q2 		$3.6M Buy
+19,615
New +$3.43M 0.25% 93

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital International Inc's VRTX Position: Q2 2026 in Review

Capital International Inc increased its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q2 2026, buying an estimated $1.19M and bringing the position to 164,407 shares worth $81.7M. The position accounts for 0.57% of the portfolio, ranked #45.

Capital International Inc first reported a position in VRTX in Q2 2019 and has held it in 28 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital International Inc held 164,407 shares of Vertex Pharmaceuticals worth $81.7M as of Q2 2026.
  • Capital International Inc bought 2,684 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.19M.
  • Vertex Pharmaceuticals made up 0.57% of Capital International Inc's portfolio in Q2 2026, its #45 holding.
  • Capital International Inc first reported a position in Vertex Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital International Inc's 13F filing for Q2 2026, filed 12 Aug 2026.